| Symbol | ALNY |
|---|---|
| Name | ALNYLAM PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 675 WEST KENDALL STREET,HENRI A. TERMEER SQUARE, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | +1 617 551-8200 |
| Fax | — |
| — | |
| Website | https://www.alnylam.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylams cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. Additional info from NASDAQ: |
2026-04-16 12:00
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
Read more
2026-04-07 20:21
McLaughlin Melissa 🔴 sold 3.9K shares of ALNYLAM PHARMACEUTICALS, INC. (ALNY) at $333.94 ($1.3M) Transaction Date: Apr 02, 2026 | Filing ID: 000014
Read more
2026-04-07 17:17
New Form 3 - ALNYLAM PHARMACEUTICALS, INC. <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0001178670-26-000012 <b>Size:</b> 9 KB
Read more
2026-04-06 20:05
📋 McLaughlin Melissa (Officer) plans to sell 2K shares of ALNYLAM PHARMACEUTICALS, INC. (at $320.10 each, total $732K) Filed: Apr 06, 2026 | ID: 000425
Read more
2026-04-06 17:32
New Form DEFA14A - ALNYLAM PHARMACEUTICALS, INC. <b>Filed:</b> 2026-04-06 <b>AccNo:</b> 0001628280-26-023924 <b>Size:</b> 866 KB
Read more
2026-03-30 17:00
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
Read more
2026-03-26 16:25
New Form SCHEDULE 13G/A - ALNYLAM PHARMACEUTICALS, INC. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000562 <b>Size:</b> 7 KB
Read more
2026-03-24 11:30
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
Read more
2026-03-06 21:13
Garg Pushkal 🔴 sold 4.7K shares of ALNYLAM PHARMACEUTICALS, INC. (ALNY) at $326.08 ($1.5M) Transaction Date: Mar 04, 2026 | Filing ID: 000063
Read more
2026-03-06 21:13
Director Greenstreet Yvonne 🔴 sold 2.9K shares of ALNYLAM PHARMACEUTICALS, INC. (ALNY) at $325.67 Transaction Date: Mar 04, 2026 | Filing ID: 000062
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04056481 | Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria | — | Acute Hepatic Porphyria | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT04125472 | Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxa… | — | Primary Hyperoxaluria | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT07223203 | TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patient… | Phase3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | Recruiting | 2026-01-16 | 2031-06-12 | ClinicalTrials.gov |
| NCT07214727 | A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease | Phase1 | Alzheimer's Disease | Recruiting | 2025-10-15 | 2030-03-06 | ClinicalTrials.gov |
| NCT07181109 | Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Ei… | Phase3 | High Risk Cardiovascular Disease | Recruiting | 2025-09-22 | 2030-09-30 | ClinicalTrials.gov |
| NCT07052903 | TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloi… | Phase3 | Transthyretin Amyloidosis With Cardiomyopathy | Recruiting | 2025-07-02 | 2032-11-30 | ClinicalTrials.gov |
| NCT06965569 | Multiple Ascending Dose Phase 1 Study of ALA-3000 | Phase1 | Treatment Resistant Depression | Completed | 2025-04-21 | 2025-12-30 | ClinicalTrials.gov |
| NCT06845202 | A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in O… | Phase1 | Obese or Overweight Healthy Volunteers | Recruiting | 2025-03-03 | 2027-08-31 | ClinicalTrials.gov |
| NCT06600321 | A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | Phase1 | Advanced Hepatocellular Carcinoma | Recruiting | 2024-12-30 | 2027-10-31 | ClinicalTrials.gov |
| NCT06675565 | A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers | Phase1 | Healthy Volunteers | Completed | 2024-11-05 | 2025-09-08 | ClinicalTrials.gov |
| NCT06585449 | A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease | Phase1 | Huntington's Disease | Recruiting | 2024-10-14 | 2028-07-05 | ClinicalTrials.gov |
| NCT06423352 | A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hype… | Phase1 | Mild to Moderate Hypertension | Completed | 2024-06-05 | 2025-07-17 | ClinicalTrials.gov |
| NCT06225544 | Lumasiran in Hyperoxalaemic Patients on Haemodialysis | Phase2 | Haemodialysis | Recruiting | 2024-04-14 | 2025-03-01 | ClinicalTrials.gov |
| NCT06272487 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hyp… | Phase2 | High Cardiovascular Risk | Completed | 2024-02-29 | 2025-12-01 | ClinicalTrials.gov |
| NCT05761301 | A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers… | Phase1 | Type 2 Diabetes Mellitus (T2DM) | Terminated | 2023-03-10 | 2025-04-03 | ClinicalTrials.gov |
| NCT05727878 | Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Partici… | Phase2 | Persistent Corneal Epithelial Defect | Terminated | 2023-02-07 | 2025-10-19 | ClinicalTrials.gov |
| NCT05661916 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodyna… | Phase1 | Transthyretin-Mediated Amyloidosis | Completed | 2023-01-16 | 2025-09-30 | ClinicalTrials.gov |
| NCT05023889 | Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amylo… | Early_Phase1 | Polyneuropathies | Active_Not_Recruiting | 2022-08-03 | 2026-02-25 | ClinicalTrials.gov |
| NCT04569903 | Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-… | Early_Phase1 | Transthyretin Amyloidosis | Withdrawn | 2022-08-01 | 2025-02-01 | ClinicalTrials.gov |
| NCT05161936 | A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney S… | Phase2 | Recurrent Calcium Oxalate Kidney Stone Disease | Terminated | 2022-01-27 | 2022-11-01 | ClinicalTrials.gov |
| NCT04982393 | BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxal… | — | Primary Hyperoxaluria Type 1 | Active_Not_Recruiting | 2021-12-13 | 2028-09-01 | ClinicalTrials.gov |
| NCT05136443 | Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection | Phase4 | Corneal Endothelial Dystrophy | Completed | 2021-11-23 | 2023-09-05 | ClinicalTrials.gov |
| NCT04936035 | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-M… | Phase2 | Hypertension | Completed | 2021-07-07 | 2024-12-05 | ClinicalTrials.gov |
| NCT04883905 | ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) | — | Acute Hepatic Porphyria | Recruiting | 2021-04-26 | 2027-04-01 | ClinicalTrials.gov |
| NCT04561518 | ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-… | — | Transthyretin-Mediated Amyloidosis | Recruiting | 2020-11-23 | 2030-09-01 | ClinicalTrials.gov |
| NCT04507269 | Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China | Phase2 | Hepatitis B, Chronic | Completed | 2020-08-18 | 2021-09-30 | ClinicalTrials.gov |
| NCT05040373 | Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program | — | Hereditary Transthyretin-mediated (hATTR) Amyloidosis | Recruiting | 2020-08-01 | 2030-10-12 | ClinicalTrials.gov |
| NCT04412863 | Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment o… | Phase2 | Chronic Hepatitis B | Completed | 2020-07-03 | 2024-03-25 | ClinicalTrials.gov |
| NCT04152200 | A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria T… | Phase3 | Primary Hyperoxaluria Type 1 | Completed | 2020-01-21 | 2025-06-23 | ClinicalTrials.gov |
| NCT04201418 | A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in… | — | Hereditary Transthyretin-mediated (ATTRv) Amyloidosis | Completed | 2019-12-18 | 2022-05-24 | ClinicalTrials.gov |
| NCT04153149 | HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloid… | Phase3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Active_Not_Recruiting | 2019-11-26 | 2026-12-02 | ClinicalTrials.gov |
| NCT03841448 | A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) | Phase2 | IgA Nephropathy (IgAN) | Terminated | 2019-09-30 | 2023-06-27 | ClinicalTrials.gov |
| NCT04122755 | Single Ascending Dose Study of ALA-1000 | Phase1 | Opioid-use Disorder | Completed | 2019-09-16 | 2021-05-03 | ClinicalTrials.gov |
| NCT03862807 | Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR… | Phase3 | Amyloidosis, Familial | Completed | 2019-03-27 | 2020-10-20 | ClinicalTrials.gov |
| NCT03759379 | HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Trans… | Phase3 | Amyloidosis, Hereditary | Completed | 2019-02-14 | 2025-11-05 | ClinicalTrials.gov |
| NCT03774784 | A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (A… | — | Amyloidosis | Terminated | 2019-01-29 | 2020-05-18 | ClinicalTrials.gov |
| NCT03767829 | A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alph… | Phase1 | ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease | Terminated | 2018-12-05 | 2020-06-25 | ClinicalTrials.gov |
| NCT03672188 | Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B | Phase1 | Chronic Hepatitis B | Completed | 2018-11-14 | 2020-09-03 | ClinicalTrials.gov |
| NCT03616899 | Safety and Efficacy of KPI-121 in Subjects With DED | Phase3 | Kerato Conjunctivitis Sicca | Completed | 2018-07-10 | 2020-02-05 | ClinicalTrials.gov |
| NCT03505853 | A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Coc… | Phase1 | Acute Intermittent Porphyria (AIP) | Completed | 2018-04-26 | 2019-01-10 | ClinicalTrials.gov |
| NCT03350451 | An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Particip… | Phase2 | PH1 | Completed | 2018-04-04 | 2023-02-07 | ClinicalTrials.gov |
| NCT03303313 | A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atyp… | Phase2 | Atypical Hemolytic Uremic Syndrome | Withdrawn | 2017-09-19 | 2018-09-12 | ClinicalTrials.gov |
| NCT03237494 | TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Moni… | — | Transthyretin Amyloidosis | Completed | 2017-07-20 | 2025-05-16 | ClinicalTrials.gov |
| NCT02949830 | A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS… | Phase1 | Acute Intermittent Porphyria | Completed | 2016-10-01 | 2021-11-05 | ClinicalTrials.gov |
| NCT02826018 | A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With … | Phase1 | Hepatitis B | Terminated | 2016-06-24 | 2017-10-01 | ClinicalTrials.gov |
| NCT02797847 | A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Hea… | Phase1 | Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) | Completed | 2016-06-07 | 2018-01-12 | ClinicalTrials.gov |
| NCT02819284 | Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Dis… | Phase3 | Dry Eye Syndromes | Completed | 2016-06-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT02793817 | Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and P… | Phase3 | Post Surgical Ocular Inflammation and Pain | Completed | 2016-06-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT02706886 | Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Ty… | Phase1 | Primary Hyperoxaluria Type 1 (PH1) | Completed | 2016-03-08 | 2019-01-23 | ClinicalTrials.gov |
| NCT02595983 | The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment … | Phase2 | Transthyretin (TTR)-Mediated Amyloidosis | Completed | 2015-10-01 | 2017-02-06 | ClinicalTrials.gov |
| NCT02510261 | The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment … | Phase3 | Amyloidosis | Completed | 2015-07-16 | 2022-11-23 | ClinicalTrials.gov |
| NCT02503683 | A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Pati… | Phase1 | Antitrypsin Deficiency Liver Disease | Terminated | 2015-07-09 | 2018-01-03 | ClinicalTrials.gov |
| NCT02452372 | A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porp… | Phase1 | Acute Intermittent Porphyria | Completed | 2015-05-06 | 2017-09-06 | ClinicalTrials.gov |
| NCT02352493 | A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunte… | Phase1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Completed | 2015-01-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT02314442 | A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevate… | Phase1 | Hypercholesterolemia | Completed | 2014-12-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02319005 | ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With … | Phase3 | Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) | Completed | 2014-12-01 | 2017-03-30 | ClinicalTrials.gov |
| NCT02292186 | A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyre… | Phase2 | TTR-mediated Amyloidosis | Completed | 2014-10-01 | 2017-02-22 | ClinicalTrials.gov |
| NCT02240784 | EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP) | — | Acute Hepatic Porphyria | Completed | 2014-08-01 | 2021-04-26 | ClinicalTrials.gov |
| NCT02245516 | Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retina… | Na | Retinal Vein Occlusion | Completed | 2014-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02252653 | DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspec… | — | Familial Amyloidotic Cardiomyopathy (FAC) | Completed | 2014-06-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02053454 | A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japane… | Phase1 | Transthyretin (TTR)-Mediated Amyloidosis | Completed | 2014-01-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01981837 | Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin … | Phase2 | TTR-mediated Amyloidosis | Completed | 2013-12-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01960348 | APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Tr… | Phase3 | TTR-mediated Amyloidosis | Completed | 2013-11-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT01961921 | The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Med… | Phase2 | TTR-mediated Amyloidosis | Completed | 2013-10-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT01814839 | A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety… | Phase1 | TTR-mediated Amyloidosis | Completed | 2013-03-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01617967 | Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloid… | Phase2 | TTR-mediated Amyloidosis | Completed | 2012-05-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01559077 | Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Hea… | Phase1 | TTR-mediated Amyloidosis | Completed | 2012-03-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01437059 | Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevate… | Phase1 | Elevated LDL-Cholesterol (LDL-C) | Completed | 2011-09-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01158079 | Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who H… | Phase1 | Solid Tumors | Completed | 2010-07-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01065935 | Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respirato… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2010-02-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00658086 | Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respirator… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2008-04-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00496821 | Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated… | Phase2 | Respiratory Syncytial Virus Infections | Completed | 2007-07-01 | 2007-11-01 | ClinicalTrials.gov |
Total clinical trials: 72
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Sterile Normal Saline (0.9% NaCl) | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Nucresiran | Other | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| ALN-4915 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07535606 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| ALN-4324 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| Placebo | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| ALN-4324 | Other | Phase PHASE1 | Obese or Overweight Healthy Volunteers | RECRUITING | NCT06845202 |
| Placebo | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Zilebesiran | Other | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-4285 | Other | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| KPI-121 1.0% Ophthalmic Suspension | DRUG | Approved | Retinal Vein Occlusion | COMPLETED | NCT02245516 |
| Vehicle of KPI-121 Ophthalmic Suspension dosed BID | DRUG | Phase PHASE3 | Post Surgical Ocular Inflammation and Pain | COMPLETED | NCT02793817 |
| KPI-121 1% Ophthalmic Suspension dosed BID | DRUG | Phase PHASE3 | Post Surgical Ocular Inflammation and Pain | COMPLETED | NCT02793817 |
| Vehicle of KPI-121 0.25% Ophthalmic Suspension | DRUG | Phase PHASE3 | Dry Eye Syndromes | COMPLETED | NCT02819284 |
| KPI-121 0.25% Ophthalmic Suspension | DRUG | Approved | Retinal Vein Occlusion | COMPLETED | NCT02245516 |
| KPI-121 | DRUG | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT02188160 |
| Vehicle | DRUG | Phase PHASE3 | Kerato Conjunctivitis Sicca | COMPLETED | NCT03616899 |
| KPI-121 Ophthalmic Suspension | DRUG | Phase PHASE3 | Kerato Conjunctivitis Sicca | COMPLETED | NCT03616899 |
| Oxycodone oral capsule | DRUG | Phase PHASE1 | Analgesia | TERMINATED | NCT03880487 |
| Placebo oral capsule | DRUG | Phase PHASE1 | Analgesia | TERMINATED | NCT03880487 |
| KP-1199 | DRUG | Phase PHASE1 | Analgesia | TERMINATED | NCT03880487 |
| buprenorphine sublingual film | DRUG | Phase PHASE1 | Opioid-use Disorder | COMPLETED | NCT04122755 |
| ALA-1000 | DRUG | Phase PHASE1 | Opioid-use Disorder | COMPLETED | NCT04122755 |
| loteprednol etabonate 0.25% ophthalmic suspension | DRUG | Phase PHASE4 | Corneal Endothelial Dystrophy | COMPLETED | NCT05136443 |
| KPI-012 Vehicle | DRUG | Phase PHASE2 | Persistent Corneal Epithelial Defect | TERMINATED | NCT05727878 |
| KPI-012 | DRUG | Phase PHASE2 | Persistent Corneal Epithelial Defect | TERMINATED | NCT05727878 |
| escitalopram, sertraline, duloxetine or venlafaxine XR | DRUG | Phase PHASE1 | Treatment Resistant Depression | COMPLETED | NCT06965569 |
| ALA-3000 | DRUG | Phase PHASE1 | Treatment Resistant Depression | COMPLETED | NCT06965569 |
| Tirzepatide | DRUG | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| ALN-2232 | DRUG | Phase PHASE1 | Obesity | RECRUITING | NCT07463846 |
| ALN-4285 | DRUG | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07295717 |
| ALN-5288 | DRUG | Phase PHASE1 | Alzheimer's Disease | RECRUITING | NCT07214727 |
| Nucresiran | DRUG | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| ALN-4324 | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus (T2DM) | RECRUITING | NCT07465224 |
| ALN-AGT01 RVR | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06675565 |
| ALN-6400 | DRUG | Phase PHASE1 | Hereditary Hemorrhagic Telangiectasia | RECRUITING | NCT06659640 |
| Pembrolizumab | DRUG | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-BCAT | DRUG | Phase PHASE1 | Advanced Hepatocellular Carcinoma | RECRUITING | NCT06600321 |
| ALN-HTT02 | DRUG | Phase PHASE1 | Huntington's Disease | RECRUITING | NCT06585449 |
| Standard of Care | OTHER | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT06360289 |
| 0.9% Sodium Chloride (placebo) | DRUG | Phase PHASE2 | Haemodialysis | RECRUITING | NCT06225544 |
| No intervention. Retrospective observation only. | OTHER | Preclinical | Chronic Inflammatory Demyelinating Polyneuropathy | UNKNOWN | NCT05940922 |
| ALN-KHK | DRUG | Phase PHASE1 | Type 2 Diabetes Mellitus (T2DM) | TERMINATED | NCT05761301 |
| ALN-TTRSC04 | DRUG | Phase PHASE1 | Transthyretin-Mediated Amyloidosis | COMPLETED | NCT05661916 |
| ALN-XDH | DRUG | Phase PHASE1 | Gout | TERMINATED | NCT05256810 |
| ALN-APP | DRUG | Phase PHASE2 | Cerebral Amyloid Angiopathy | RECRUITING | NCT06393712 |
| Zilebesiran | DRUG | Phase PHASE3 | High Risk Cardiovascular Disease | RECRUITING | NCT07181109 |
| Olmesartan | DRUG | Phase PHASE2 | Hypertension | COMPLETED | NCT05103332 |
| Amlodipine | DRUG | Phase PHASE2 | Hypertension | COMPLETED | NCT05103332 |
| Indapamide | DRUG | Phase PHASE2 | Hypertension | COMPLETED | NCT05103332 |
| patisiran | DRUG | Phase EARLY_PHASE1 | Polyneuropathies | ACTIVE_NOT_RECRUITING | NCT05023889 |
| Computer algorithm for ATTR | DEVICE | Phase EARLY_PHASE1 | Transthyretin Amyloidosis | WITHDRAWN | NCT04569903 |
| ALN-HSD | DRUG | Phase PHASE1 | Nonalcoholic Steatohepatitis | TERMINATED | NCT04565717 |
| Placebos | DRUG | Phase PHASE2 | Atypical Hemolytic Uremic Syndrome | WITHDRAWN | NCT03999840 |
| cemdisiran | DRUG | Phase PHASE2 | Atypical Hemolytic Uremic Syndrome | WITHDRAWN | NCT03999840 |
| Irbesartan-Matching Placebo | DRUG | Phase PHASE1 | Hypertension | COMPLETED | NCT03934307 |
| Irbesartan | DRUG | Phase PHASE1 | Hypertension | COMPLETED | NCT03934307 |
| ALN-AGT01-Matching Placebo | DRUG | Phase PHASE1 | Hypertension | COMPLETED | NCT03934307 |
| ALN-AGT01 | DRUG | Phase PHASE2 | Hypertension | COMPLETED | NCT04936035 |
| ALN-AAT02 | DRUG | Phase PHASE1 | ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease | TERMINATED | NCT03767829 |
| Vutrisiran | DRUG | Phase PHASE3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy | RECRUITING | NCT07223203 |
| 5-probe cocktail | DRUG | Phase PHASE1 | Acute Intermittent Porphyria (AIP) | COMPLETED | NCT03505853 |
| Cemdisiran | DRUG | Phase PHASE2 | IgA Nephropathy (IgAN) | TERMINATED | NCT03841448 |
| Givosiran | DRUG | Preclinical | Acute Hepatic Porphyria | APPROVED_FOR_MARKETING | NCT04056481 |
| ALN-HBV | DRUG | Phase PHASE1 | Hepatitis B | TERMINATED | NCT02826018 |
| ALN-TTRSC02 | DRUG | Phase PHASE1 | Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) | COMPLETED | NCT02797847 |
| Placebo | DRUG | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT02188160 |
| Lumasiran | DRUG | Phase PHASE2 | Haemodialysis | RECRUITING | NCT06225544 |
| Revusiran | DRUG | Phase PHASE2 | Transthyretin (TTR)-Mediated Amyloidosis | COMPLETED | NCT02595983 |
| ALN-AAT | DRUG | Phase PHASE1 | Antitrypsin Deficiency Liver Disease | TERMINATED | NCT02503683 |
| givosiran (ALN-AS1) | DRUG | Phase PHASE1 | Acute Intermittent Porphyria | COMPLETED | NCT02452372 |
| ALN-CC5 | DRUG | Phase PHASE1 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | COMPLETED | NCT02352493 |
| ALN-PCSSC | DRUG | Phase PHASE1 | Hypercholesterolemia | COMPLETED | NCT02314442 |
| Revusiran (ALN-TTRSC) | DRUG | Phase PHASE3 | Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) | COMPLETED | NCT02319005 |
| ALN-TTRSC (revusiran) for subcutaneous administration | DRUG | Phase PHASE2 | TTR-mediated Amyloidosis | COMPLETED | NCT01981837 |
| ALN-TTR02 (patisiran) administered by intravenous (IV) infusion | DRUG | Phase PHASE2 | TTR-mediated Amyloidosis | COMPLETED | NCT01961921 |
| patisiran (ALN-TTR02) | DRUG | Preclinical | TTR-mediated Amyloidosis | APPROVED_FOR_MARKETING | NCT02939820 |
| ALN-TTRSC (revusiran) | DRUG | Phase PHASE1 | TTR-mediated Amyloidosis | COMPLETED | NCT01814839 |
| Patisiran | DRUG | Preclinical | Transthyretin-mediated Amyloidosis With Cardiomyopathy | NO_LONGER_AVAILABLE | NCT05505838 |
| ALN-TTR02 | DRUG | Phase PHASE1 | TTR-mediated Amyloidosis | COMPLETED | NCT01559077 |
| ALN-PCS02 | DRUG | Phase PHASE1 | Elevated LDL-Cholesterol (LDL-C) | COMPLETED | NCT01437059 |
| Sterile Normal Saline (0.9% NaCl) | DRUG | Phase PHASE3 | Transthyretin Amyloidosis With Cardiomyopathy | RECRUITING | NCT07052903 |
| ALN-TTR01 | DRUG | Phase PHASE1 | Transthyretin Mediated Amyloidosis (ATTR) | COMPLETED | NCT01148953 |
| Normal Saline | DRUG | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT01065935 |
| ALN-VSP02 | DRUG | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01158079 |
| normal saline | DRUG | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT00658086 |
| ALN-RSV01 | DRUG | Phase PHASE2 | Respiratory Syncytial Virus Infections | COMPLETED | NCT01065935 |
Total products: 89